Date: 2012-07-17
Type of information: Licensing agreement
Compound: EB66® cell line
Company: Vivalis (France) Merial, a Sanofi company (France)
Therapeutic area: Veterinary medicine
Type agreement: licensing
R&D
Action mechanism:
Disease:
Details: Vivalis has executed a new research license agreement with Merial to evaluate the production of additional animal vaccine candidates using Vivalis’s EB66® cell line. Previously in 2005 and 2010, Merial signed two EB66® commercial license agreements for the production of veterinary vaccines. This license represents the fifth EB66® cell line agreement signed since January 1, 2012. Terms of the agreement were not disclosed.
Financial terms:
Latest news:
